Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 7/2012

01-07-2012 | Original Research Article

Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients

Authors: Dirk Jan A. R. Moes, Rogier R. Press, Jan den Hartigh, Tahar van der Straaten, Johan W. de Fijter, Prof. Dr Henk-Jan Guchelaar

Published in: Clinical Pharmacokinetics | Issue 7/2012

Login to get access

Abstract

Background and Objective

Everolimus is a novel macrolide immunosuppressant used in the prevention of acute and chronic rejection of solid organ transplants. Everolimus is being actively investigated worldwide as a non-nephrotoxic alternative for calcineurin inhibitors. Its highly variable pharmacokinetics and narrow therapeutic window make it difficult to maintain an adequate exposure to prevent serious adverse effects. The primary objective of this study was to improve prediction of everolimus systemic exposure in renal transplant patients by describing the pharmacokinetics of everolimus and identifying the influence of demographic factors and a selection of polymorphisms in genes coding for ABCB1, CYP3A5, CYP2C8 and PXR. The secondary objective of this study was to develop a limited sampling strategy to enable prediction of everolimus exposure in an efficient way and to compare it with the widely used trough blood concentration (Ctrough) monitoring.

Methods

A total of 783 blood samples were obtained from 53 renal transplant patients who had been switched from a triple therapy of ciclosporin, mycophenolate mofetil and prednisolone to a calcineurin inhibitor-free dual therapy of everolimus (twice daily) and prednisolone. Everolimus blood concentrations were analysed in whole blood using liquid chromatography-tandem mass spectrometry during routine therapeutic drug monitoring targeting an area under the blood concentration-time curve from time zero to 12 hours (AUC12) of 120 μg · h/L. A population pharmacokinetic model was developed and demographic factors and genetic polymorphisms in genes coding for ABCB1, CYP3A5, CYP2C8 and PXR were included as covariates. In addition, a limited sampling strategy was developed.

Results

Maintaining everolimus systemic exposure at an AUC12 of 120 120 μg · h/L resulted in low rejection rates but considerable numbers of adverse events and toxicity. Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance= 17.9 L/h; volume of distribution of the central compartment after oral administration [V1/F]= 148 L and first-order absorption rate constant [ka] = 7.36 h−1). Ideal body weight was significantly related to V1/F. None of the selected polymorphisms in genes coding for enzymes involved in distribution and metabolism of everolimus had a significant influence on everolimus pharmacokinetics. The pharmacokinetic limited sampling model (Ctrough and whole blood drug concentration at 2 hours postdose [C2]) resulted in a significantly improved prediction of everolimus exposure compared with the widely used Ctrough monitoring.

Conclusion

A two-compartment pharmacokinetic model with lag-time describing the concentration-time profile of oral everolimus in renal transplant patients has been developed using pharmacokinetic modelling. Ideal body weight significantly influenced V1/F of everolimus; however, the selected polymorphisms in genes coding for ABCB1, CYP3A5, CYP2C8 and PXR had no clinically relevant effect on everolimus pharmacokinetics. Everolimus Ctrough and C2 as a limited sampling model can be used to accurately estimate everolimus systemic exposure, an improvement over the widely used Ctrough monitoring.
Literature
1.
Höcker B, Tönshoff B. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Paediatr Drugs 2011 Feb 1; 13(1): 49–69PubMedCrossRef
2.
Pape L, Offner G, Kreuzer M, et al. De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 2010 Oct; 10(10): 2349–54PubMedCrossRef
3.
Bemelman FJ, de Maar EF, Press RR, et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009 Aug 15; 88(3): 421–8PubMedCrossRef
4.
Budde K, Lehne G, Winkler M, et al. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. J Clin Pharmacol 2005 Jul 1; 45(7): 781–91PubMedCrossRef
5.
Kacar S, Gurkan A, Karaca C, et al. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. Transplant Proc 2010 Nov; 42(9): 3513–6PubMedCrossRef
6.
Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011 Mar 5; 377(9768): 837–47PubMedCrossRef
7.
Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43(2): 83–95PubMedCrossRef
8.
Jacobsen W, Serkova N, Hausen B, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001 Mar; 33(1–2): 514–5PubMedCrossRef
9.
Istrate MA, Nussler AK, Eichelbaum M, et al. Regulation of CYP3A4 by pregnane X receptor: the role of nuclear receptors competing for response element binding. Biochem Biophys Res Commun 2010 Mar 19; 393(4): 688–93PubMedCrossRef
10.
Kniepeiss D, Renner W, Trummer O, et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin Transplant 2011 Feb; 25(1): 146–50PubMedCrossRef
11.
Picard N, Rouguieg-Malki K, Kamar N, et al. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation 2011 Mar 27; 91(6): 652–6PubMedCrossRef
12.
Kovarik JM, Hsu CH, McMahon L, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001 Sep; 70(3): 247–54PubMedCrossRef
13.
Chan L, Hartmann E, Cibrik D, et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation 2010 Jul 15; 90(1): 31–7PubMedCrossRef
14.
Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992 May; 22(3): 155–63PubMedCrossRef
15.
Moes DJAR, Press RR, de Fijter JW, et al. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation. Ther Drug Monit 2010 Aug; 32(4): 413–9PubMedCrossRef
16.
Koster RA, Dijkers ECF, Uges DRA. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood. Ther Drug Monit 2009 Feb; 31(1): 116–25PubMedCrossRef
17.
Lindbom L, Pihlgren P, Jonsson EN, et al. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005 Sep; 79(3): 241–57PubMedCrossRef
18.
19.
20.
21.
Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 Aug; 9(4): 503–12PubMedCrossRef
22.
Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn 2005 Dec; 32(5–6): 703–18PubMedCrossRef
23.
24.
Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 2004 Oct; 26(5): 499–505PubMedCrossRef
25.
Kovarik J, Kalbag J, Figueiredo J, et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002 Jan 1; 42(1): 95–9PubMedCrossRef
26.
Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001 Jan; 69(1): 48–56PubMedCrossRef
27.
Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer, 2005
28.
Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur J Clin Pharmacol 2010 Jun; 66(6): 579–90PubMedCrossRef
29.
Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002 Feb; 22(2): 154–9PubMedCrossRef
30.
Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001 Jul; 11(5): 447–58PubMedCrossRef
31.
Qiu H, Mathäs M, Nestler S, et al. The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenet Genomics 2010 Mar; 20(3): 167–78PubMedCrossRef
32.
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet 2010 Apr 1; 49(4): 207–21PubMedCrossRef
33.
Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011 Nov; 57(11): 1574–83PubMedCrossRef
34.
Fanta S, Niemi M, Jönsson S, et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 2008 Feb; 18(2): 77–90PubMedCrossRef
35.
Zhao W, Fakhoury M, Deschênes G, et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of myco-phenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol 2010 Nov; 50(11): 1280–91PubMedCrossRef
36.
Benkali K, Prémaud A, Picard N, et al. Tacrolimus population pharm-acokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009; 48(12): 805–16PubMedCrossRef
37.
Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003 Jun; 43(6): 555–64PubMed
38.
Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009 Apr; 31(2): 187–97PubMedCrossRef
39.
Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 2009 Dec; 86(6): 609–18PubMedCrossRef
40.
Le Meur Y, Djebli N, Szelag J-C, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006 Jul; 80(1): 51–60PubMedCrossRef
41.
van Schaik RHN, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002 Oct; 48(10): 1668–71PubMed
42.
Kang D, Schwartz JB, Verotta D. Sample size computations for PK/PD population models. J Pharmacokinet Pharmacodyn 2005 Dec; 32(5–6): 685–701PubMedCrossRef
43.
Bertrand J, Comets E, Laffont CM, et al. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. J Pharmacokinet Pharmacodyn 2009 Aug; 36(4): 317–39PubMedCrossRef
44.
Finnström N, Ask B, Dahl M-L, et al. Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes. Pharmacogenomics J 2002; 2(2): 111–6PubMedCrossRef
45.
Lamba V, Panetta JC, Strom S, et al. Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther 2010 Mar; 332(3): 1088–99PubMedCrossRef
46.
Lee C-Y, Lai T-Y, Wu Y-M, et al. Gene expression of P-glycoprotein and cytochrome P450 3A4 in peripheral blood mononuclear cells and correlation with expression in liver. Transplant Proc 2010 Apr; 42(3): 834–6PubMedCrossRef
47.
Kuypers DR. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant 2008; 13(3): 11–8PubMed
Metadata
Title
Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients
Authors
Dirk Jan A. R. Moes
Rogier R. Press
Jan den Hartigh
Tahar van der Straaten
Johan W. de Fijter
Prof. Dr Henk-Jan Guchelaar
Publication date
01-07-2012
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 7/2012
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/11599710-000000000-00000

Other articles of this Issue 7/2012

Clinical Pharmacokinetics 7/2012 Go to the issue

Original Research Article

Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis

Original Research Article

Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics

Review Article

Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications

Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin